Sparrow Pharmaceuticals

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cardiometabolic therapeutics to improve outcomes for patients with type 2 diabetes and related metabolic conditions. The company leverages insights into intracellular cortisol regulation to address an underlying cause of metabolic dysfunction, via its lead candidate clofutriben, an HSD-1 inhibitor designed to lower intracellular cortisol. This approach aims to improve glycemic control and metabolic health in patients underserved by current therapies across multiple organ systems. Headquartered in the biotech landscape, Sparrow emphasizes precision approaches to cortisol-related metabolic diseases.